Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP4297 plus temozolomide in extensive-stage small cell lung cancer
CTR20221169Phase 2Completed
- Sponsor
- Junpai Yingshi Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of senaparib in small cell lung cancer (SCLC), sponsored by Junpai Yingshi Pharmaceutical. Started May 2022; status: completed.
02
Drugs
senaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221169.